BioSpace News Archive

Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced participation in the following industry and scientific conferences in June:

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the presentation of mature Phase 2 clinical trial results describing the positive impact of trilaciclib in combination with a TROP2 ADC on overall survival and tolerability compared to SG alone based on historical data from the ASCENT trial1.

Arcturus Therapeutics Holdings Inc. announced Arcturus will be presenting Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032, an inhaled investigational mRNA therapeutic to treat CF, at the 47th European Cystic Fibrosis Conference on June 7, 2024.

Axsome Therapeutics, Inc. announced that data from its industry-leading portfolio of novel products for CNS disorders will be presented at the 2024 American Society of Clinical Psychopharmacology Annual Meeting, being held May 28-31, 2024, in Miami Beach, Florida.

Labcorp, a global leader of innovative and comprehensive laboratory services, announced that members of the executive management team will participate in a presentation at the 44th Annual William Blair Growth Stock Conference on Tuesday, June 4 at 2:00 p.m..

Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website.

Galvanize announced that it received U.S. Food and Drug Administration 510 regulatory clearance for the INUMI Flex endoscopic needle for use with the Aliya® PEF System for soft tissue ablation.

Alkermes plc announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies, taking place June 1-5, 2024 in Houston.

Turn Biotechnologies announced an exclusive global licensing agreement with pharmaceutical manufacturer HanAll Biopharma to develop groundbreaking medicines for the treatment of age-related eye and ear conditions.

Glaukos Corporation today announced that its management is scheduled to participate in the following upcoming investor conferences.